The NIH clinical trial aims to address the knowledge gap regarding vaccine use in adolescent populations. A clinical trial ...

The MVA-BN vaccine, licensed in the United States to prevent smallpox and mpox, is well tolerated and seems effective in adolescents.

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, ...

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to a ...

A comprehensive review in JAMA outlines monkeypox's clinical presentation and management, stressing the need for increased ...

A National Institutes of Health (NIH)-funded clinical trial of an mpox vaccine in adolescents found it was safe and generated ...

Interim results of a phase 2 trial indicate that the mpox vaccine MVA-VN has an immune response in adolescents similar to ...

After approving Bavarian Nordic’s mpox vaccine in September for use in adults, the World Health Organisation has given the ...

The World Health Organization has approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17, a group considered ...